Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | HTR1F | P30939 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5212691 | 0.92 | KMT2A (0.61) | KMT2AHTR1FPKMCASP3SENP8 | |
| SCHEMBL5212363 | 0.87 | TCF4 (0.59) | KDM1AKMT2AHTR1FMEN1ALDH1A1 | |
| SCHEMBL5213124 | 0.87 | HTR1F (0.56) | KMT2AHTR1FMEN1ALDH1A1TDP1 | |
| SCHEMBL5214543 | 0.86 | ITGA1 (0.58) | KMT2AHTR1FPKMHSD17B2MEN1 | |
| SCHEMBL5212060 | 0.86 | HTR1F (0.68) | KMT2AHTR1FMEN1KDM4ECYP3A4 | |
| SCHEMBL5213119 | 0.86 | EGFR (0.57) | KMT2AHTR1FMEN1ALDH1A1CYP3A4 | |
| SCHEMBL5210843 | 0.86 | ITGA1 (0.58) | KMT2AHTR1FMEN1ALDH1A1KDM4E | |
| SCHEMBL5212756 | 0.85 | HTR1F (0.54) | KMT2AHTR1FPKMALDH1A1HPGD | |
| SCHEMBL5216484 | 0.84 | TCF4 (0.64) | KMT2AHTR1FMEN1ALDH1A1KDM4E | |
| SCHEMBL5212974 | 0.84 | ATIC (0.62) | KDM1AKMT2AHTR1FHSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1153013-B1 | 5-HT1F AGONISTS | LILLY CO ELI (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1841427-A2 | COMPOSITIONS AND THERAPEUTIC METHODS UTILIZING A COMBINATION OF A 5-HT1F INHIBITOR AND AN NSAID | Pozen, Inc. (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20060178349-A1 | Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID | POZEN INC. (US) | 2006-08-10 | — | — | US | disclosed |
| WO-2006081127-A2 | COMPOSITIONS AND THERAPEUTIC METHODS UTILIZING A COMBINATION OF A 5-HT1F INHIBITOR AND AN NSAID | POZEN INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| US-6777428-B1 | INHIBIT PEPTIDE EXTRAVASATION DUE TO STIMULATION OF THE TRIGEMINAL GANGLIA, AND ARE THEREFORE USEFUL FOR THE TREATMENT OF MIGRAINE AND ASSOCIATED DISORDERS | ELI LILLY AND COMPANY | 2004-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178349-A1 | Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID | HTR1F, HTR1A, HTR1E | KDM1A 2554/4885MAOA 274/4885KMT2A 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.